Nitric oxide solution
Alternative Names: RespiNOSLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Barts and The London NHS Trust; Queen Mary Medical School
- Developer Barts and The London NHS Trust; Edixomed; Queen Mary Medical School
- Class Anti-infectives; Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antituberculars; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bronchiectasis; Diabetic foot ulcer; Ventilator associated pneumonia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Diabetic-foot-ulcer in United Kingdom (Topical)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Ventilator-associated-pneumonia (Prevention) in United Kingdom (Inhalation, Aerosol)
- 01 Aug 2013 Clinical trials in Diabetic foot ulcer in United Kingdom (Topical) before August 2013